DiaSorin SpA
MIL:DIA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
58.36
106.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IT |
|
DiaSorin SpA
MIL:DIA
|
3.8B EUR |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
188.6B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
186.9B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
138.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.1B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
130.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
55.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.5B USD |
Loading...
|
Market Distribution
| Min | -79 476% |
| 30th Percentile | 3.9% |
| Median | 8.7% |
| 70th Percentile | 14.4% |
| Max | 813.7% |
Other Profitability Ratios
DiaSorin SpA
Glance View
In the heart of the global healthcare landscape, DiaSorin SpA stands as a testament to innovation and precision in the field of biotechnology. Founded in 1968 in Italy, the company built its reputation on developing and producing diagnostic tests that help identify and monitor diseases. With a primary focus on immunodiagnostic and molecular diagnostic products, DiaSorin excels in creating high-quality, reliable solutions that clinicians and labs around the world depend on. Their product portfolio ranges widely, covering infectious diseases, oncology, endocrinology, and more. By leveraging cutting-edge research and development processes, DiaSorin not only prioritizes accuracy and efficiency in its testing solutions but also adapts to the ever-evolving demands of the medical world, cementing its role as a leader in diagnostic innovation. From a business perspective, DiaSorin's revenue streams are deeply intertwined with its prowess in developing proprietary testing technologies, including both instruments and consumables. The company operates with a dual-channel business model where it sells diagnostic machines to laboratories, hospitals, and clinics while simultaneously providing the reagents and kits necessary for these machines' continuous operation. This approach ensures not only a sale of sophisticated equipment but also a recurring revenue stream from the consumables needed for diagnostics. With a strategic emphasis on research and partnerships, DiaSorin has expanded its reach globally, ensuring its products meet diverse regional healthcare requirements. Through a combination of robust product offerings and strategic global expansion, DiaSorin continues to thrive and maintain its position as a pivotal contributor to the field of diagnostic medicine.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for DiaSorin SpA is 22.8%, which is below its 3-year median of 22.9%.
Over the last 3 years, DiaSorin SpA’s Operating Margin has decreased from 30.3% to 22.8%. During this period, it reached a low of 20.7% on Dec 31, 2023 and a high of 30.3% on Jun 30, 2022.